Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
AFM-24I by Affimed for Colorectal Cancer: Likelihood of Approval
AFM-24I is under clinical development by Affimed and currently in Phase II for Colorectal Cancer. According to GlobalData, Phase II...
AFM-24I by Affimed for Lung Cancer: Likelihood of Approval
AFM-24I is under clinical development by Affimed and currently in Phase II for Lung Cancer. According to GlobalData, Phase II...
AFM-24I by Affimed for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval
AFM-24I is under clinical development by Affimed and currently in Phase II for Bile Duct Cancer (Cholangiocarcinoma). According to GlobalData,...
AFM-24I by Affimed for Glioblastoma Multiforme (GBM): Likelihood of Approval
AFM-24I is under clinical development by Affimed and currently in Phase II for Glioblastoma Multiforme (GBM). According to GlobalData, Phase...
AFM-24I by Affimed for Gastric Cancer: Likelihood of Approval
AFM-24I is under clinical development by Affimed and currently in Phase II for Gastric Cancer. According to GlobalData, Phase II...
AFM-24I by Affimed for Pancreatic Cancer: Likelihood of Approval
AFM-24I is under clinical development by Affimed and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase II...
AFM-24I by Affimed for Head And Neck Cancer: Likelihood of Approval
AFM-24I is under clinical development by Affimed and currently in Phase II for Head And Neck Cancer. According to GlobalData,...
AFM-24I by Affimed for Cervical Cancer: Likelihood of Approval
AFM-24I is under clinical development by Affimed and currently in Phase II for Cervical Cancer. According to GlobalData, Phase II...
AFM-24I by Affimed for Ovarian Cancer: Likelihood of Approval
AFM-24I is under clinical development by Affimed and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase II...
AFM-24I by Affimed for Metastatic Colorectal Cancer: Likelihood of Approval
AFM-24I is under clinical development by Affimed and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData, Phase...
AFM-24I by Affimed for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval
AFM-24I is under clinical development by Affimed and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction. According to...
AFM-24I by Affimed for Transitional Cell Cancer (Urothelial Cell Cancer): Likelihood of Approval
AFM-24I is under clinical development by Affimed and currently in Phase II for Transitional Cell Cancer (Urothelial Cell Cancer). According...
AFM-24I by Affimed for Esophageal Cancer: Likelihood of Approval
AFM-24I is under clinical development by Affimed and currently in Phase II for Esophageal Cancer. According to GlobalData, Phase II...
AFM-24I by Affimed for Renal Cell Carcinoma: Likelihood of Approval
AFM-24I is under clinical development by Affimed and currently in Phase II for Renal Cell Carcinoma. According to GlobalData, Phase...
AFM-24I by Affimed for Metastatic Hepatocellular Carcinoma (HCC): Likelihood of Approval
AFM-24I is under clinical development by Affimed and currently in Phase II for Metastatic Hepatocellular Carcinoma (HCC). According to GlobalData,...
AFM-24I by Affimed for Metastatic Renal Cell Carcinoma: Likelihood of Approval
AFM-24I is under clinical development by Affimed and currently in Phase II for Metastatic Renal Cell Carcinoma. According to GlobalData,...
AFM-24I by Affimed for Non-Small Cell Lung Cancer: Likelihood of Approval
AFM-24I is under clinical development by Affimed and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData,...
Risk adjusted net present value: What is the current valuation of Affimed's AFM-24I?
AFM-24I is a monoclonal antibody commercialized by Affimed, with a leading Phase II program in Adenocarcinoma Of The Gastroesophageal Junction....